Genomics and proteomics: A new approach for assessing thrombotic risk in autoimmune diseases

Lupus

Volumn 17, Issue 10, 2008, Pages 905-915

  López Pedrera, Chary ^a   Barbarroja, N ^a   Aguirre, M A ^a   Torres, L A ^a   Velasco, F ^a   Cuadrado, M J ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Autoimmune diseases; Cardiovascular disease; Genomics proteomics

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; VASCULOTROPIN;

ANTIPHOSPHOLIPID SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DNA MICROARRAY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION PROFILING; GENOMICS; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; GENETIC PROCEDURES; GENETICS; PATHOLOGY;

AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; GENETIC TECHNIQUES; GENOMICS; HUMANS; PROTEOMICS; RISK ASSESSMENT;

EID: 59649128312     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308095285     Document Type: Review

References (99)

1. Villalta D Tozzoli R Tonutti E Bizzaro N. The laboratory approach to the diagnosis of autoimmune diseases: Is it time to change. Autoimmun Rev 2007;6:359-365.
2. Shoenfeld Y Sherer Y Harats D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001;22:293-295.
3. Shoenfeld Y Gerli R Doria A. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-3347.
4. Chan SM Utz PJ. The challenge of analyzing the proteome in humans with autoimmune diseases. Ann N Y Acad Sci 2005;1062:61-68.
5. Dotzlaw H Eggert M Neeck G Schulz M. Spots, blots, peaks and chips: proteomic approaches in autoimmune diseases. Curr Pharm Des 2006;12:3699-3706.
6. Solomon DH Karlson EW Rimm EB. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-1307.
7. Jurcut C Jurcut R Tanasescu C. Cardiovascular risk and rheumatoid arthritis: From mechanisms of atherosclerosis to therapeutic approach. Rom J Intern Med 2004;42:659-669.
8. Dessein PH Jaffe BI Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634-R643.
9. del Rincón I Freeman GL Haas RW O'Leary DH Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherothrombosis. Arthritis Rheum 2005;52:3413-3423.
10. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002;89:33D-38D.
11. Sherer Y Shoenfeld Y. Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99-106.
12. Zal B Kaski JC Arno G. Heat-shok protein 60-reactive CD4+CD28null T cells in patients with acute coronary sundrome. Circulation 2004;109:1230-1235.
13. Gerli R Schillaci G Giordano A. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744-2748.
14. Swanberg M Lidman O Padyukov L. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005;37:486-494.
15. D'Cruz DP Khamashta MA Hughes GRV. Systemic Lupus Erythematosus. Lancet 2007;369:587-596.
16. Szekanecz Z Shoenfeld Y. Lupus and cardiovascular disease: The facts. Lupus 2006;15:3-10.
17. Roman MJ Crow MK Lockshin MD. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412-3419.
18. Rhew EZ Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus - role of inflammatory mechanisms. Autoimmun Rev 2006;5:101-105.
19. Bruce IN. Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin. Best Pract Res Clin Rheumatol 2005;19:823-838.
20. Manzi S Meilahn EN Rairie JE. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408-415.
21. Kiss E Fazekas B Tarr T Muszbek L Zeher M Szegedi G. Lipid profile in patients with systemic lupus erythematosus with special focus on lipoprotein(a) in lupus nephritis. Orv Hetil 2004;145:217-222 (HungMed J).
22. Rajagopalan S Somers EC Brook RD. Endothelial cell apoptosis in systemic lupus erythematosus: A common pathway for abnormal vascular function and thrombosis propensity. Blood 2004;103:3677-3683.
23. Takahashi T Kalka C Masuda H. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-438.
24. Asahara T Takahashi T Masuda H. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-3972.
25. Lee PY Li Y Richards HB. Type I interferon as novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in SLE. Arthritis Rheum 2007;56:3759-3769.
26. Espinosa G Cervera R Font J Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003;2:86-93.
27. Koike T Bohgaki M Amengual O Atsumi T. Antiphospholipid antibodies. Lessons from the bench. J Autoimmun 2007;28:129-133.
28. Amengual O Atsumi T Khamashta MA Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-281.
29. Atsumi T Khamashta MA Amengual O Hughes GR. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997;77:222-223.
30. Cuadrado MJ Lopez-Pedrera C Khamashta MA. Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834-841.
31. Dobado-Berrios PM Lopez-Pedrera C Velasco F Aguirre MA Torres A Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999;82:1578-1582.
32. Dobado-Berrios PM Lopez-Pedrera C Velasco F Cuadrado MJ. The role of TF in the antiphospholipid syndrome. Arthritis Rheum 2001;44:2467-2476.
33. Dunoyer-Geindre S de Moerloose P Galve-de Rochemonteix B Reber G Kruithof EK. NFkappa B is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002;88:851-857.
34. Lopez-Pedrera C Buendia P Cuadrado MJ. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK1/ERK pathway. Arthritis Rheum 2006;54:304-311.
35. Vega-Ostertag M Harris EN Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004;50:2911-2919.
36. Bohgaki M Atsumi T Yamashita Y. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene y monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies. Int Immunol 2004;16:1633-1641.
37. Vega-Ostertag M Casper K Swerlick R Ferrara D Harris EN Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52:1545-1554.
38. Montiel-Manzano G Romay-Penabad Z Papalardo de Martinez E. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci 2007;1108:540-553.
39. Vega-Ostertag ME Ferrara DE Romay-Penabad Z. Role of p38 mitogen-activated protein kinase in antiphospholipid-antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007;5:1828-1834.
40. Brown LF Detmar M Claffey K. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS 1997;79:233-239.
41. Chen J Bierhaus A Shiekofer S. Tissue factor - a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86:334-345.
42. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
43. Williams FMK Parmar K Hughes GRV Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000;84:742-746.
44. Cuadrado MJ Buendia P Velasco F. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006;4:2461-2469.
45. Soltesz P Veres K Lakos G Kiss E Muszbek L Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: A retrospective study of 637 patients. Lupus 2003;12:302-307.
46. Jimenez S García-Criado MA Tassies D. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44: 756-761.
47. Hasunuma Y Matsuura E Makita Z Katahira T Nishi S Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-573.
48. George J Harats D Gilburd B. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation 1999;99:2227-2230.
49. Shoenfeld Y Sherer Y George J Harats D. Autoantibodies associated with atherosclerosis. Ann Med 2000;32 (Suppl. I): 37-40.
50. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996;5:442-447.
51. Veres K Lakos G Kerenyi A. Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004;13:423-427.
52. Undas A Celiska-Lowenhoff M Kaczor M Musial J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004;91:1065-1077.
53. Krysiak R Okopien B Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003;63:1821-1854.
54. Undas A Brummel-Ziedins E Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005;25:1-8.
55. Ferrara DE Swerlick R Casper K. Fluvastatin inhibits-upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004;2:1558-1563.
56. Meroni PL Raschi E Testoni C. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870-2878.
57. Ferrara DE Liu X Espinola RG. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003;48:3272-3279.
58. Centola M Frank MB Bolstad AI. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: A potential breakthrough diagnostic and individualized therapy-design tool. Scand J Immunol 2006;64:236-242.
59. Alwine JC Kemp DJ Stark GR. A method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethil-paper and hybridization with DNA probes. Proc Natl Acad Sci USA 1977;74:5350-5354.
60. Gerhard DS Kawasaki ES Bancroft FC Szabo P. Localization of unique gene by direct hybridization. Proc Natl Acad Sci USA 1981;78:3755-3759.
61. Pietu G Alibert O Guichard V. Novel gene transcripts preferentially expressed in human muscles revealed by quantitative hybridization of a high density cDNA array. Genome Res 1996;6:492-503.
62. Brown PO Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999; 21 (Suppl. 1): 33-37.
63. Blanco-Colio LM Martin-Ventura JL Vivanco F Michel JB Meilhac O Egido J. Biology of atherosclerotic plaques: What we are learning from proteomic analysis. Cardiovasc Res 2006;72:18-29.
64. Gygi SP Corthals GL Zhang Y Rochon Y Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000;17:9390-9395.
65. Aebersold R Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
66. DeSouza L Diehl G Rodrigues MJ. Search for cancer markers from endometrial tissue using differentially labeled tags iTRAQ and ICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2005;4:377-386.
67. Hueber W Utz PJ Steinman L Robinson WH. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 2002;4:290-295.
68. Hueber W Kidd BA Tomooka BH. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005;52:2645-2655.
69. Hueber W Tomooka BH Zhao X. Proteomic analysis of secreted proteins in early rheumatoid arthritis: Anti-citrulline autoreactivity is associated with upregulation of proinflammatory cytokines. Ann Rheum Dis 2007;66:712-719.
70. Liao H Wu J Kuhn E. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:3792-3803.
71. Kim CW Cho EH Lee YJ Kim YH Hah Y-S Kim DR. Disease-specific proteins from rheumatoid arthritis patients. J Korean Med Sci 2006;21:478-484.
72. Edwards CJ Feldman JL Beech J. Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med 2007;13:40-58.
73. Dotzlaw H Schulz M Eggert M Neeck G. A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim Biophys Acta 2004;1696:121-129.
74. Schulz M Dotzlaw H Mikkat S Eggert M Neeck G. Proteomic analysis of peripheral blood mononuclear cells: Selective protein processing observed in patients with rheumatoid arthritis. J Proteome Res 2007;6:3752-3759.
75. Vyse TJ Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 1998;16:261-292.
76. Mandel M Achiron A. Gene expression studies in systemic lupus erythematosus. Lupus 2006;15:451-456.
77. Li QZ Zhou J Wandstrat AR. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 2007;147:60-70.
78. Rus V Atamas SP Shustova V. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol 2002;102:283-290.
79. Qing X Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2004;3:505-509.
80. Mandel M Gurevich M Pauzner R Kaminski N Achiron A. Autoimmunity gene expression portrait: Specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004;138:164-170.
81. Silva GL Junta CM Mello SS. Profiling meta-analysis reveals primarily gene coexpression concordance between systemic lupus erythematosus and rheumatoid arthritis. Ann N Y Acad Sci 2007;1110:33-46.
82. Farkas L Beiske K Lund-Johansen F Brandtzaeg P Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosis lesions. Am J Pathol 2001;159:237-243.
83. Blanco P Palucka AK Gill M Pascual V Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-1543.
84. Baechler EC Batliwalla FM Karypis G. Interferon-inducible gene expression signature in peripheral blood cell of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-2615.
85. Bennett L Paluka AK Arce E. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-723.
86. Nikpour M Dempsey AA Urowitz MB Gladman DD Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis 2007 (in press).
87. Graham RR Kyogoku C Sigurdsson S. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007;104:6758-6763.
88. Bauer JW Baechler EC Petri M. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491.
89. Li QZ Xie C Wu T. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005;115:3428-3439.
90. Yasuda S Stevens RL Terada T. Defective expression of Ras guanyl nucleotide-releasing protein 1 in a subset of patients with systemic lupus erythematosus. J Immunol 2007;179:4890-4900.
91. Zhou H Wolberg AS Roubey RAS. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004;104:2353-2358.
92. Cuadrado MJ Buendia P Aguirre A. Proteomic analysis of purified monocytes from patients with antiphospholipid syndrome: Identification of new proteins involved in the origin and the development of thrombotic events. Arthritis Rheum 2006;54:S560-S561.
93. Potti A Bild A Dressman HK Lewis DA Nevins JR Ortel TL. Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood 2006;107:1391-1396.
94. Bernales I Fullaondo A Marin-Vidalled MJ. Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. Genes Immun 2008;9:38-46.
95. Hamid C Norgate K D'Cruz DP. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007;66:1000-1007.
96. Tyson KL Weissberg PL Shanahan CM. Heterogeneity of gene expression in human atheroma unmasked using cDNA representational difference analysis. Physiol Genomics 2002;9:121-130.
97. Martinet W Schrijvers DM De Meyer GR. Gene expression profiling of apoptosis-related genes in human atherosclerosis: Upregulation of death-associated protein kinase. Arterioscler Thromb Vasc Biol 2002;22:2023-2029.
98. Jang WG Kim HS Park DG. Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smoth muscle cells with or without alpha lipoic acid. Proteomics 2004;4:3383-3393.
99. Verhoeckx KC Bijlsma S de Groene EM Witkamp RF van der Greef J Rodenburg RJ. A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. Proteomics 2004;4:1014-1028.